Cancer/Tumor Profiling Market worth 61.87 Billion USD by 2021

PUNE, India, December 6, 2016 /PRNewswire/ --

According to a new market research report "Cancer/Tumor Profiling Market by Application (Diagnostic, Personalized Medicine, Research), Technique (Genomics, Proteomics, Metabolomics, Epigenetics), Technology (Next-generation Sequencing, qPCR, In-situ Hybridization, Microarray) - Forecast to 2021" published by MarketsandMarkets, the global market is poised to reach USD 61.87 Billion by 2021 from USD 25.82 Billion in 2016, at a CAGR of 19.1% from 2016 to 2021.

     (Logo: http://photos.prnewswire.com/prnh/20160303/792302 )

Browse 81 market data Tables and 34 Figures spread through 157 Pages and in-depth TOC on "Cancer/Tumor Profiling Market"

http://www.marketsandmarkets.com/Market-Reports/cancer-tumor-profiling-market-1250.html

Early buyers will receive 10% customization on this report. 

This report provides a detailed overview of major drivers, restraints, challenges, opportunities, current market trends and strategies impacting the global market along with estimates and forecast of revenue.

Major factors fueling market growth are increasing number of cancer cases across the globe, the increasing utility of biomarkers, and availability of funding for cancer research. On the other hand, high capital investments and low benefit ratio for biomarkers used in cancer/tumor profiling are expected to limit Cancer/Tumor Profiling Market growth to a certain extent. Factors such as the increasing demand for personalized medicine and point-of-care diagnostic tests in cancer/tumor profiling are expected to offer a wide range of growth opportunities for players in the Cancer/Tumor Profiling Market.

Speak to our research experts: 

http://www.marketsandmarkets.com/speaktoanalyst.asp?id=1250

The global Cancer/Tumor Profiling Market is segmented on the basis of technology, technique, application, and region. On the basis of applications, the Cancer/Tumor Profiling Market is broadly segmented into personalized medicine, biomarker discovery, diagnostics, prognostics, and research applications. The personalized medicine segment is expected to account for the largest share of the global cancer/tumor profiling application market in 2016. Advantages such as reduced probability to adverse drug reactions, better prediction of cancer, and better targeted therapy for the treatment of cancer are contributing to the large share of the personalized medicine segment in the Cancer/Tumor Profiling Market.

Furthermore, based on technique, the Cancer/Tumor Profiling Market is segmented into genomics, proteomics, epigenetics, and metabolomics. The genomics segment is expected to account for the largest share of the cancer/tumor profiling technique market in 2016. Factors such as increasing investments, grants, and funds by governments; growing research in the field of genomics; and rising application of genomic sequencing in diagnostics are contributing to the growth of this segment.

Based on technology, the global Cancer/Tumor Profiling Market is broadly divided into next-generation sequencing, quantitative PCR, in situ hybridization, immunohistochemistry, and microarray. The next-generation sequencing segment is expected to account for the largest share of the cancer/tumor profiling technology market in 2016. Factors such as reduction in sequencing costs, technology advancements in sequencing platforms, research laboratories and academicians promoting the use of NGS, and increasing awareness on NGS products and services are contributing to the growth of this segment.

North America (comprising the U.S. and Canada) is expected to account for the largest share of the global Cancer/Tumor Profiling Market in 2016, followed by Europe. Increasing research funding and presence of a large number of market players and research institutes are propelling the growth of the North American Cancer/Tumor Profiling Market. The Asia-Pacific region is expected to grow at the highest CAGR in the forecast period. In recent years, the Asia-Pacific market for cancer/tumor profiling has witnessed significant growth due to the rising incidence of cancer, increasing demand for better healthcare services in developing economies such as India and China, rising number of contract research organizations (CROs), and increasing focus of international players on emerging markets.

The Cancer/Tumor Profiling Market is dominated by established players such as Illumina Inc. (U.S.), QIAGEN N.V. (Netherlands), NeoGenomics Laboratories (U.S.), HTG Molecular Diagnostic (U.S.), and Genomic Health Inc. (U.S.).

Browse Related Reports: 

Cancer Diagnostics Market by Technology (ELISA, ELFA, PCR, NGS, Immunohistochemistry, Microarray, Imaging (MRI, CT, PET, Ultrasound, Mammography), Biopsy), Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma) - Forecast to 2020

Published date: June 2015

http://www.marketsandmarkets.com/Market-Reports/cancer-diagnostics-market-186559121.html

Cancer Biomarkers Market by Tumor (Breast, Lung, Prostate), Type (Protein & Genetic Biomarkers), Profiling Technology (Proteomics, Genomics, Imaging, Immunoassay), Application (Diagnostic, Drug Discovery, Prognostic) & Geography - Global Forecast to 2020

Published date: August 2015

http://www.marketsandmarkets.com/Market-Reports/oncology-biomarkers-202.html  

About MarketsandMarkets:

MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.

M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Subscribe Reports from Healthcare Domain @  

http://www.marketsandmarkets.com/Knowledgestore.asp

Contact:
Mr. Rohan
MarketsandMarkets
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States
Tel: 1-888-600-6441
Email: sales@marketsandmarkets.com

Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/medical-devices

Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets

SOURCE MarketsandMarkets